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Eosinophil Major Basic Protein-1 Does Not Contribute to
Allergen-Induced Airway Pathologies in Mouse Models of
Asthma1
Karen L. Denzler, Steven C. Farmer, Jeffrey R. Crosby, Michael Borchers, Grzegorz Cieslewicz,
Kirsten A. Larson,2 Stephania Cormier-Regard, Nancy A. Lee,3 and James J. Lee3
The relationship between eosinophils and the development of Ag-induced pulmonary pathologies, including airway hyper-respon-
siveness, was investigated using mice deficient for the secondary granule component, major basic protein-1 (mMBP-1). The loss
of mMBP-1 had no effect on OVA-induced airway histopathologies or inflammatory cell recruitment. Lung function measurements
of knockout mice demonstrated a generalized hyporeactivity to methacholine-induced airflow changes (relative to wild type);
however, this baseline phenotype was observable only with methacholine; no relative airflow changes were observed in response
to another nonspecific stimulus (serotonin). Moreover, OVA sensitization/aerosol challenge of wild-type and mMBP-12/2 mice
resulted in identical dose-response changes to either methacholine or serotonin. Thus, the airway hyper-responsiveness in murine
models of asthma occurs in the absence of mMBP-1.The Journal of Immunology,2000, 165: 5509–5517.
T he complexity of a disease-state such as asthma reflects itspolygenic origin (1), the involvement of both systemicand mucosal immune cascades (2), and the exacerbating
effects of environmental factors (e.g., airborne allergens (3) and
viral infection (4)). Although a wide variation exists with respect
to presenting symptoms, asthma is characterized by three common
features: reversible airflow limitation, specific airway histopathol-
ogies and cellular infiltrates, and airway hyper-responsiveness
(AHR)4; i.e., the development of bronchoconstriction in response
to nonspecific stimuli. Additional indicators of asthma include mu-
cus overproduction (5), pulmonary expression of leukotrienes (6)
and Th2 inflammatory cytokines (e.g., IL-4 and IL-5) (7), in-
creases in serum IgE levels (8), and often (70–90% of reported
cases) the increased presence of eosinophils in the airway mucosa
and lumen (9). The pathophysiological manifestations of asthma
correlate with this eosinophilic airway infiltration (3). Moreover,
eosinophil influx has been associated with the development of lung
dysfunction even in mild cases of asthma (9). Thus, the appearance
of pulmonary pathologies and eosinophil recruitment to the lung
implies a causative relationship.
A growing body of literature now exists suggesting that the
release of eosinophil secondary (sometimes referred to as specific)
ranule proteins (ESGPs) is critical to eosinophil-mediated activ-
ities and may be responsible for many of the observed pathologies
associated with allergic respiratory disease. Potential deleterious
effects of ESGPs include not only activities leading to airway dam-
age and lung dysfunction (e.g., AHR) (10), but also direct effects
on several other cell types. On a molar basis, the most abundant
human ESGPs are eosinophil major basic proteins (MBPs). MBPs
are small cationic proteins (;12 kDa; pI 10–12) that colocalize
with the characteristic electron-dense crystalline core of eosinophil
secondary granules (11). In the mammalian orders examined to
ate, including Primata (humans) and Rodentia (mice), MBPs are
encoded by two genes that share considerable sequence identity
(12–14). The relative function(s) of each MBP in a given species
is not known. For example, the reported differences in biological
activities between the human MBPs (hMBP-1 and -2) are nominal,
and assessments of the proteins stored in the granule show that
nearly all the MBP in eosinophils is hMBP-1 (;10:1) (13). More-
over, many clinical studies have shown that the deposition of
hMBP-1 is a diagnostic marker of the inflammation occurring in
the lungs of asthmatics, and accompanies airway epithelial dam-
age, lung remodeling, and perturbations of lung function (15).
The correlative association between AHR and MBP-1 (and
therefore eosinophils) has been documented in several mammalian
species, including humans (15–18). Several studies have defined a
potential causative mechanism resulting in AHR by linking eosin-
ophil effector function, mediated by MBP-1 release, and musca-
rinic receptor dysfunction (17–20). However, the link between eo-
sinophils and AHR using mouse models of pulmonary
inflammation is more tenuous and controversial. For example,
many studies disassociate AHR from the recruitment (and presum-
ably activation) of eosinophils to the lung. These studies can be
divided into three groups: 1) studies that demonstrate that airway
eosinophilia can occur without AHR (21); 2) mouse models that
show that AHR occurs in the absence of a significant airways
eosinophilia (22–26); and 3) studies that disassociate the kinetics
of eosinophil recruitment to the lung and the development of AHR
(27). Moreover, several studies in the mouse link AHR directly
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with T cell activities independently of eosinophil effector function
(25, 27–32). Therefore, while a preponderance of evidence sug-
gests that eosinophil effector functions are responsible for Ag-in-
duced AHR, data from in vivo studies using mouse models have,
in some cases, been in conflict with this hypothesis.
To define the specific role(s) of mMBP-1 in the development of
Ag-induced AHR, we created a gene knockout mouse line defi-
cient for this protein. These mice display baseline perturbations of
airway reactivity (relative to wild-type littermates) in response to
methacholine, but show no homeostatic phenotype when airway
reactivity is assessed by serotonin provocation. Furthermore, re-
gardless of the nonspecific stimulus used to assay reactivity, the
loss of mMBP-1 did not obviate Ag-induced AHR in an OVA
sensitization/challenge model. These data suggest that although
mMBP-1 expression, even at the low levels observed in naive
mice, is sufficient to alter uniquely muscarinic receptor function(s),
the AHR occurring in murine models of asthma is not causatively
linked to mMBP-1 release from eosinophils.
Materials and Methods
Targeting of the mMBP-1 locus and the generation/propagation
of knockout mice
A mMBP-1 gene targeting vector was constructed using genomic DNA
fragments flanking a 1.55-kb region that includes exons 2, 3, and 4 of this
gene (12). The targeting vector replaces these exons with a neomycin re-
sistance cassette (PGK-neo) and also includes a herpes simplex virus thy-
midine kinase gene (HSV-TK) as a negative selection marker (Fig. 1A).
GK-129 embryonic stem (ES) cells (43 107) (33) were electroporated with
25 mg of linearized DNA and subjected to positive selection for PGK-neo
with G418 (400mg/ml) and negative selection for the presence of the
HSV-TK marker with gancyclovir (2mM). Clones containing heterozy-
gous disruptions of the gene were identified by Southern blot analysis with
a probe (Probe 1) flanking the 59homology region (i.e., not contained
within the targeting construct). The presence of a single integration event
was verified by hybridization with aneo-derived DNA fragment (Probe 2).
Gene-targeted cells were injected into C57BL/6J blastocysts to create chi-
meric animals that were subsequently bred to 129/SvJ mice, allowing the
transmission of this allele on a 129 inbred background (129/Ola/Hsd3129/
SvJ). All mice were maintained in microisolator cages housed in a specific
pathogen-free animal facility. The sentinel cages within this animal colony
were negative for viral Abs and the presence of known mouse pathogens.
Protocols and studies involving animals were conducted in accordance
with National Institutes of Health and Mayo institutional guidelines.
Mice carrying the mMBP-1-targeted allele were genotyped using PCR
and DNA recovered from tail biopsies. Animals were identified as wild
type (1/1), heterozygous (mMBP-11/2), or homozygous (mMBP-12/2)
using a three-primer strategy. The location and orientation of the primers
is shown in Fig. 1A: primer P1, 59-ATGCCACTGTGAGACAGGGTA
AGG-39; primer P2, 59-CAGATGAAGAGCAGACGCTC-39; and primer
P3, 59-GAACCAGCTGGGGCTCGAG-39. Primers P1 and P2 anneal
uniquely to the wild-type locus and produce an 874-bp PCR amplicon.
Primers P1 and P3 anneal to the targeted locus and produce a 683-bp PCR
amplicon. Southern blots were prepared with GeneScreen Plus membranes
(NEN, Boston, MA) and hybridized with the32P-labeled DNA probes iden-
tified in Fig. 1.
Determination of mMBP-1 gene expression
RT-PCR to identify potential mMBP-1 transcripts from specific tissues
were performed using template cDNA derived from the reverse transcrip-
tion of 1 mg of total RNA (bone marrow, liver, lung, and spleen). PCR
were performed using a primer set from exon 2 (P4, 59-TCTACTTCTG
GCTCTTCTAGTCGGG-39) and exon 6 (P5, 59-GACACAGTGAGATA
GACGCCAGTG-39) to generate a 631-bp amplicon. The reaction program
consisted of an initial denaturation step of 94°C for 5 min, followed by 30
cycles of 94°C (30 s), 60°C (1 min), 72°C (2 min), and a final 72°C (5-min)
extension period. Parallel PCR using primers derived from theb-actin gene
showed that all samples of RNA were reverse transcribed.
Electron microscopy of peripheral eosinophils
Eosinophils for microscopy were generated from peritoneal cavity exu-
dates of mice sensitized/challenged withMesocestoides cortiprotein ex-
tract (12). Exudate cells (20–40% eosinophils) were collected by lavage
and concentrated by low speed centrifugation (8 min/1000 rpm, 4°C). The
leukocytes in this pellet were resuspended directly in Trump’s fixative (4%
formaldehyde, 0.5% glutaraldehyde, and 84 mM NaH2PO4, pH 7.2) and
stored at room temperature before application to electron microscopy grids.
OVA-induced allergic airway inflammation
Assessments of lung function and histopathology were performed on
OVA-sensitized/saline-treated vs OVA-challenged 8- to 16-wk-old mice.
All mice were immunized by two i.p. injections (100ml) of OVA (20 mg;
crude grade IV, Sigma) complexed with 2.25 mg of Imject Alum
(Al(OH)3/Mg(OH)2; Pierce, Rockford, IL) on days 0 and 14. Sensitized
mice were then challenged with an OVA aerosol (1% OVA prepared in
saline) for 20 min on days 24, 25, and 26 using an ultrasonic nebulizer (De
Vilbiss, Somerset, PA); control animals received a saline-only aerosol. The
mice were assessed for pulmonary cellular infiltrates, histopathologies, and
lung function on day 28.
Assessments of allergic airway inflammation: pulmonary cellular
infiltrates and histological changes in the lung
The methods and analyses assessing cellular infiltrates associated with
bronchoalveolar lavage (BAL) and collagen digests of whole lungs were
described previously (34). Histopathologic changes in the lungs, including
mucus cell content of the airway epithelium, were assessed from tissues
excised and fixed in 10% formalin (lungs were inflated with a fixed volume
(0.5 ml) of fixative). The lung samples were washed free of formalin with
13 PBS and subsequently dehydrated through an ethanol series before
equilibration in xylene and embedding in paraffin. Sections (4mm) were
mounted on slides and stained with either periodic acid-Schiff (counter-
stained with hematoxylin/methylgreen) or alcian blue, pH 2.5 (counter-
stained with nuclear fast red). Parasagittal sections were analyzed by
brightfield microscopy. The mucus content in the airway epithelium of
mice from different groups was based on the evaluation of;40 airways
(both proximal and distal)/mouse (n5 5 animals/group). Relative com-
parisons of mucus content were made between cohorts of animals using an
imaging program (Image ProPlus) quantifying the data as an airway mucus
index: [(average alcian blue staining intensity of the airway epithelium)3
(area of airway epithelium staining with alcian blue)]/[(total area of the
conducting airway epithelium)3 (total number of airways assessed)].
Immunohistochemical detection of eosinophils in paraffin-
embedded tissue
Sections of lung tissue (4mm) were assessed for the infiltration of eosin-
ophils using mAbs specific for individual secondary granule proteins.
mAbs were raised against native mMBP-1 and the collective group of
murine eosinophil-associated RNases (mEARs) using protein purified from
peripheral blood eosinophils derived from an IL-5 transgenic line of mice
(35). Individual Abs were selected on the basis of reactivity to native pro-
tein in an ELISA format as well as their utility as a detection reagent using
formalin-fixed paraffin sections. The specificity of the mMBP-1 (rat mAb
14.7.4) and mEARs (rat mAb 32.1.3) protein A-Sepharose-purified Abs
was determined by competition assays with purified native protein. Immu-
nohistochemical staining was performed with diaminobenzidene-peroxi-
dase detection reagents according to the manufacturer’s instructions (Vec-
tor, Burlingame, CA). Briefly, lung sections were deparaffinized and
washed in PBS (13PBS), and endogenous peroxidase activity was
quenched in a methanol buffer (80% methanol/0.6% hydrogen peroxide) in
preparation for Ab staining. Methanol-peroxide-treated sections were
washed with 13PBS, digested (10 min, 25°C) with pepsin (Zymed, San
Francisco, CA), and blocked by incubation at room temperature in 1.5%
normal goat serum for 30 min. The blocked sections were treated with the
rat mAbs at final concentrations of 0.4mg/ml (diluting the Abs in 1.5%
normal goat serum/PBS for 1 h at room temperature). The slides were
subsequently washed free of primary Ab with several changes of 13PBS,
and a secondary reagent (polyclonal rabbit anti-rat IgG Abs conjugated to
HRP (Dako, Carpinteria, CA)) was bound at 13mg/ml (room temperature,
1 h) before histochemical development using diaminobenzidene-peroxi-
dase. The sections were counterstained with methyl green in preparation
for photomicroscopy.
Determination of airway reactivity in response to provocation
with nonspecific stimuli
AHR was assessed by inducing airflow obstruction with either a metha-
choline or serotonin aerosol using a noninvasive protocol (34, 36). This
methodology uses unrestrained conscious mice that are placed into the
main chamber of a plethysmograph (Buxco Electronics, Troy, NY). Pres-
sure differences between this chamber and a reference chamber were used
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to extrapolate minute volume, tidal volume, breathing frequency, and en-
hanced pause (PENH). PENH is a dimensionless parameter that is a func-
tion of total pulmonary airflow in mice (i.e., the sum of the airflows in the
upper and lower respiratory tracts) during the respiratory cycle of the an-
imal. This parameter closely correlates to lung resistance as measured by
traditional invasive techniques using ventilated animals (36). Dose-re-
sponse data were plotted as the percent baseline PENH vs the log10 of the
methacholine or serotonin solution (milligrams per milliliter) used to gen-
erate the aerosol. There were no statistically significant differences (Tukey-
Kramer highest significant difference test) in observed baseline PENH
values (6SEM) between each cohort of animals used in these studies:
wild-type (1/1) saline, 0.706 0.07; wild-type (1/1) OVA, 0.636 0.08;
mMBP-12/2 saline, 0.516 0.02; and mMBP-12/2 OVA, 0.52 6 0.04.
Statistical analyses
Pairs of groups were compared using Student’st tests. Thep value for
significance was set at 0.05, and values for all measurements are expressed
as the mean6 SEM.
Results
Generation of mMBP-1 gene knockout mice
We previously reported the identification and cloning of mMBP-1,
the murine orthologue of hMBP-1 (12). Genomic clones represent-
ing this locus were used to develop a targeting construct designed
to replace exons 2, 3, and 4 of the mMBP-1 gene with a neomycin
resistance cassette (Fig. 1A). These exons include the signal se-
quence associated with protein secretion, the propolypeptide pre-
cursor that is proteolytically cleaved, and the N-terminal 54 aa of
the mature mMBP-1 protein stored in the secondary granule. The
targeting construct was electroporated into GK129 ES cells, and
clones heterozygous for the induced mMBP-1 mutation were iden-
tified by Southern blot as shown in Fig. 1B. Targeted ES cell
clones were injected into C57BL/6J blastocysts, and highly chi-
meric male mice were bred with 129/SvJ females to generate
germline mice. Homozygous mMBP-1 knockout mice on a 129
ackground were generated by interbreeding of heterozygous sib-
lings (Fig. 1C). We have not observed any anomalies associated
with the breeding of mMBP-12/2 mice. Homozygous animals
were produced from these sibling intercrosses at the expected
Mendelian frequency, and matings of homozygous mice produced
litters of a size and frequency equivalent to wild-type or heterozy-
gous animals.
Gene activity was assessed using RT-PCR in the lung, liver,
spleen, and bone marrow. These data show that homozygous mu-
tant mice did not accumulate mMBP-1 transcripts in any of the
tissues examined (Fig. 1D). Expression of the mMBP-1 gene was
restricted to wild-type and mMBP-11/2 mice, and as reported pre-
viously (35), steady state transcripts were limited to known sites of
eosinophilopoiesis (i.e., bone marrow and spleen).
Loss of mMBP-1 has ultrastructural effects on eosinophil
secondary granules
The number of secondary granules in mature eosinophils (derived
from the peritoneal cavity of mice sensitized/challenged with a
parasite (Mesocestoides corti) protein extract (12)) appeared to be
unaffected by deletion of the mMBP-1 gene. The average number
of granules per cross-sectional area, as determined by electron mi-
croscopy, was the same in wild-type (29.96 3.6) and mMBP-
12/2 (32.16 3.8) eosinophils. In addition, the size of the granules
FIGURE 1. Targeted disruption of the mouse
eosinophil MBP-1 gene.A, Restriction maps of the
targeting construct and the mMBP-1 locus before
and after homologous recombination. Probes used
for Southern blot analyses are shown as black bars
(Probes 1 and 2), and PCR primers are shown as
labeled arrows (P1-P5). B, Southern blot ofEcoRV-
digested genomic DNA derived from potential re-
combinant ES cell clones with Probe 1. Probe 1 is a
HindIII/PstI 0.6-kb fragment that hybridizes with a
5.0-kb band from the wild-type locus and a 4.2-kb
band from the targeted locus. Three negative and
three positive clones for targeted deletion of the
mMBP-1 gene are shown.C, Genotyping of
mMBP-1 mice. ES cells of clone 52 were injected
into C57BL/6J blastocysts to generate chimeric
mice, and homozygous mMBP-1 knockout mice
were generated by interbreeding of heterozygous
siblings. Mice were genotyped by PCR analysis of
genomic DNA derived from tail biopsies to differ-
entiate between wild-type (1/1), heterozygous
(mMBP-11/2), and homozygous mMBP-12/2
mice.D, Murine MBP-1 transcript accumulation in
knockout mice. Steady state mMBP-1 derived tran-
scripts were detected only in wild-type (1/1) and
heterozygous (mMBP-11/2) mice using RT-PCR.
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in each group of mice (i.e., cross-sectional area) was indistinguish-
able. However, Wright-Giemsa-stained mMBP-12/2 eosinophils
lacked much of the intense color associated with the secondary
granules of these cells, suggesting that although the granules were
present, they no longer had enough cationic character to bind eosin
efficiently (data not shown). The identification of secondary gran-
ules in eosinophils is based primarily on electron microscopy
showing the presence of an electron-dense crystalline core
uniquely associated with this granule. In human eosinophils, elec-
tron immunogold staining using an anti-hMBP-1 Ab has shown
that hMBP-1 localizes to the crystalline core (11). An examination
of electron micrographs of eosinophils recovered from the perito-
neal cavity ofM. corti-sensitized/challenged mice revealed that
mMBP-1-deficient animals lack the electron-dense core associated
with secondary granules (Fig. 2). This observation shows that
the core structure in mouse eosinophil granules is dependent on the
presence of mMBP-1, but does not exclude the possibility that the
core may also be dependent on other molecules contained within
the secondary granule, including the other MBP gene family mem-
ber (i.e., mMBP-2). It is also noteworthy that the secondary gran-
ules of heterozygous animals contain electron-dense cores that
were identical with the granule cores from wild-type mice. Al-
though we have no quantitative data with regard to mMBP-1 pro-
duction in heterozygous mice, this observation suggests that core
formation is not sensitive to the;50% decrease in mMBP-1 syn-
thesis that one might expect in mMBP-11/2 mice.
OVA-induced recruitment of eosinophils to the lung is not
dependent on mMBP-1 expression
The importance of mMBP-1 to eosinophil effector function was
assessed using an established OVA model of allergic pulmonary
inflammation, which included i.p. sensitization of the mice with
OVA and an adjuvant, followed by several OVA aerosol chal-
lenges of the lung (seeMaterials and Methods). Fig. 3Acompares
the number and composition of leukocytes found in the BAL fluid
of wild-type and mMBP-12/2 mice in response to an aerosol chal-
lenge with saline or OVA. Whereas aerosol challenge with saline
alone had no effect on the homoeostatic levels of cells in the lumen
of either wild-type or mMBP-12/2 mice (i.e., eosinophils were not
recruited to the lumen and comprise,1% of the cells in the air-
FIGURE 2. The secondary granules of mMBP-
12/2 eosinophils are devoid of electron-dense core
structures. Eosinophils from peritoneal cavity exu-
dates of parasite Ag-sensitized/challenged mice (12)
were fixed and subjected to electron microscopy.A,
Electron photomicrographs showing clusters of sec-
ondary granules from wild type (1/1), mMBP-11/2,
and mMBP-12/2 mice (original magnification,
369,000).B, Single granules from mice of each ge-
notype at high magnification (original magnification,
3512,500).
FIGURE 3. The OVA-induced eosinophilia of the airway lumen and
interstitial regions are unaffected in mMBP-12/2 mice.A, The cellularity of
BAL fluid from sensitized wild-type and mMBP-12/2 mice was assessed
in response to either a saline or OVA aerosol challenge (n5 6–11 animals/
group). The cellularity of each animal cohort is expressed as the product of
the total number of cells recovered and the percentages of each cell type
derived from differentials (Wright-stained cytocentrifuge preparations) of
300 cells. Data represent the mean6 SEM. B, Parenchymal leukocyte
cellularity from sensitized wild-type and mMBP-12/2 mice (n 5 6–11
animals/group) was assessed by collagenase digestion of perfused lungs.
Data are expressed as the means (6SEM), counting a minimum of 300
cells/sample. Mf, macrophage; Lym, lymphocyte; Eos, eosinophil; Neu,
neutrophil; Mono, monocyte.p, p , 0.05, wild-type/mMBP-12/2 saline
control groups vs OVA-treated mice.
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way), the pulmonary inflammation associated with OVA challenge
in both wild-type and mMBP-12/2 mice was accompanied by the
selective recruitment of eosinophils to the airway lumen. The re-
cruitment of eosinophils to the airways of OVA-challenged
mMBP-12/2 mice was indistinguishable from that in wild-type
littermates. Eosinophil trafficking to the interstitial regions of the
lung in mMBP-12/2 mice was also unaffected relative to that in
wild-type littermates, as differential counts of leukocytes recov-
ered from collagen-digested whole lungs showed equal numbers of
eosinophils recruited to the lung in response to OVA challenge
(Fig. 3B).
Immunohistochemistry using a rat mAb specific for mMBP-1
(rmAb 14.7.4) demonstrated that the eosinophils recruited to the
lungs of knockout mice are, as expected, devoid of mMBP-1 (Fig.
4). These data also demonstrated that mMBP-1-containing eosin-
ophils are a homeostatic resident population within the paren-
chyma of wild-type mice at baseline (i.e., OVA sensitized/saline
challenged; Fig. 4A), that increases dramatically in response to an
OVA aerosol provocation (Fig. 4B). In contrast, this mAb failed to
detect the presence of mMBP-1-containing eosinophils in the
lungs of knockout mice, either at baseline (Fig. 4C) or after an
OVA aerosol provocation (i.e., OVA-sensitized/OVA-challenged;
Fig. 4D). However, the spatial distribution of eosinophils within
the pulmonary interstitium of mMBP-12/2 mice was nonetheless
unaffected as a consequence of the absence of mMBP-1. Recruited
eosinophils were identified in knockout mice by immunohisto-
chemistry using a rat mAb specific for another eosinophil second-
ary granule protein group, the mEARs (rmAb 32.1.3). These data
demonstrated that eosinophils were recruited to perivascular and
peribronchial regions of the lungs of both OVA-treated wild-type
and mMBP-12/2 mice with no difference in the relative distribu-
tion of these cells between either group of mice (Fig. 4,E andF).
Murine MBP-1-deficient mice show no difference relative to
wild-type animals with respect to the histopathologies that
develop in response to OVA challenge
OVA-treated wild-type and mMBP-12/2 mice each displayed the
same airway changes, including bronchiolar-associated leukocyte
aggregates, airway epithelial cell hypertrophy, and goblet cell hy-
perplasia (Fig. 5,A andC, vs Fig. 5,B andD, respectively). Fur-
thermore, the periodic acid-Schiff-stained sections of Fig. 5 also
show that airway epithelial mucus content of both wild-type and
mMBP-12/2 mice increased dramatically in response to OVA sen-
sitization/challenge. A quantitative assessment of airway epithelial
mucus demonstrates that the extent of OVA-induced mucus pro-
duction in wild-type and mMBP-12/2 mice is identical (Fig. 5E).
I summary, mMBP-12/2 mice displayed no differences in OVA-
induced pulmonary histopathology relative to wild-type animals,
suggesting that many, if not all, histologic changes associated with
allergic inflammation in mouse models are not contingent upon the
release of mMBP-1 from eosinophils recruited to the lung.
The AHR that occurs in OVA sensitization/challenge models of
asthma in mice is not dependent on mMBP-1
The relationship between the development of AHR and mMBP-1
expression was initially examined by assessing baseline methacho-
line responsiveness in naive animals. Surprisingly, the methacho-
line dose-response curves (means of single-animal measurements)
FIGURE 4. Murine MBP-1 is not necessary for the
recruitment of eosinophils to the lung or specific com-
partments within the pulmonary interstitium of
OVA-sensitized/challenged mice. The recruitment of
mMBP-1-containing eosinophils to the lungs of wild-
type and mMBP-12/2 mice was assessed by immuno-
histochemistry using a rat mAb specific for mMBP-1
(rmAb 14.7.4). Saline control groups (i.e., OVA sen-
sitized/saline challenged):A, wild-type; C, mMBP-
12/2. OVA-challenged groups (i.e., OVA sensitized/
OVA challenged): B, wild-type; D, MBP-12/2.
Eosinophils were also localized within the perivascu-
lar and peribronchial regions of the lung by immuno-
histochemistry using a rat mAb specific for mEARs
(rmAb 32.1.3). These photographs represent tissue
sections from OVA-sensitized/challenged wild-type
(E) and mMBP-12/2 (F) mice.
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showed that the threshold dose for methacholine-induced airflow
changes in wild-type mice was lower than the dose required to
induce equivalent changes in knockout mice (Fig. 6A). Moreover,
the absolute magnitude of these methacholine-induced changes
was significantly higher in wild-type mice relative to mMBP-12/2
littermates. This baseline phenotype, however, was observable
only with methacholine; no airflow changes were observed be-
tween wild-type and mMBP-12/2 mice in response to another
nonspecific stimulus (serotonin provocation; Fig. 6B). The unique
ability of methacholine to induce airflow perturbations in naive
mMBP-12/2 mice suggests that mMBP-1 is a homeostatic ligand
of one or more pulmonary muscarinic receptors.
Studies of airway reactivity in the knockout mice were extended
further by examining the relative effects of Ag sensitization/chal-
lenge using an OVA model system. Fig. 7 compiles data compar-
ing either methacholine (A) or serotonin (B) dose-dependent reac-
tivity changes in OVA-sensitized/challenged wild-type and
mMBP-12/2 mice (n5 8–10/group) relative to control groups. In
response to methacholine provocation (Fig. 7A), three striking dif-
ferences regarding the absolute values of the responses obtained
from each genotype are apparent. 1) Saline-treated mMBP-12/2
mice were hyporeactive relative to saline-treated wild-type mice
(effective dose 200% (ED200) 5 36.26 6.9 vs 12.56 1.1 mg/ml,
respectively;p , 0.03), confirming that in the absence of mMBP-1
the observed baseline reactivity in response to methacholine is
attenuated relative to that in wild-type animals. 2) The threshold
dose for methacholine-induced airflow changes in OVA-sensi-
tized/challenged mMBP-12/2 mice was also two to three times the
amount of methacholine necessary to produce the same changes in
OVA-treated wild-type mice (ED200 5 11.0 6 1.6 vs 4.36 0.2
mg/ml, respectively;p , 0.03)). 3) Airway reactivity in response
to the methacholine dose inducing the maximal observed PENH
difference between wild-type and mMBP-12/2 mice (i.e., 25 mg/
ml) is markedly less (;50% decrease) in both saline- and OVA-
treated mMBP-12/2 mice relative to the responses observed in
wild-type mice (p , 0.02). The implication of these differences is
that the relative shift in the methacholine dose-response curves is
the same in both genotypes. OVA provocation (relative to a gen-
otype-matched saline control group) of either wild-type (ED200 5
4.36 0.2 vs 12.56 1.1 mg/ml, respectively;p , 0.01) or mMBP-
12/2 (ED2005 11.06 1.6 vs 36.26 6.9 mg/ml, respectively;p ,
0.01) mice resulted in an;60% decrease in the threshold dose for
methacholine-induced airflow changes. Thus, allergen-induced in-
creases in methacholine-mediated airflow changes (i.e., AHR) oc-
cur in the absence of mMBP-1. This lack of an effect on allergen-
induced airflow changes in mMBP-1 knockout mice was
confirmed using serotonin as an alternative nonspecific stimulus
(Fig. 7B). OVA-sensitized/challenged wild-type and mMBP-12/2
mice each displayed identical increases in serotonin-induced air-
flow changes relative to naive control groups of mice, which dis-
played no differences in their baseline responses.
Discussion
The disassociation of mMBP-1 expression by eosinophils and the
development of Ag-induced pulmonary changes in a murine model
of asthma would suggest that the release of this ESGP is not a
FIGURE 5. OVA-induced histopathologic pul-
monary changes occur in mMBP-12/2 mice. Lung
sections from wild-type and mMBP-12/2 mice were
stained with periodic acid-Schiff (PAS) and counter-
stained with hematoxylin/methyl green. This figure
shows representative parasagittal sections that in-
clude large conducting airways. The insert photo-
graphs in each panel are representative examples of
the staining that occurs in smaller more distal bron-
chioles. Wild-type (A) and homozygous (B)
mMBP-1 knockout mice were sensitized with OVA/
alum and challenged with a saline aerosol. OVA/
alum-sensitized-OVA aerosol-challenged wild-type
(C) and homozygous mMBP-1 knockout mice (D).
Note that both wild-type and mMBP-12/2 mice dis-
play identical patterns of PAS-positive airway epi-
thelial mucus staining in response to OVA sensiti-
zation/challenge (Cand D, respectively).E, The
increase in airway epithelial mucus content is unaf-
fected in OVA-sensitized/challenged mMBP-12/2
mice relative to wild-type littermates. Mucus con-
tent indexes were derived from five animals per
group (two to four sections per animal). All evalu-
ations of histopathology, including the quantitation of
mucus content, were performed in duplicate as inde-
pendent observer-blinded assessments.p, p , 0.05,
wild-type/mMBP-12/2 saline control groups vs OVA-
treated mice.
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causative event associated with allergic inflammation in this
model. The extent of this disassociation was broad, as the loss of
mMBP-1 had no observable effect on Ag-induced eosinophil re-
cruitment, airway histopathologies (including mucus overproduc-
tion and goblet cell metaplasia), and perturbations of lung func-
tion. The only observed effect of the mMBP-1 deficiency was a
baseline attenuation of airway reactivity in response to methacho-
line provocation. However, this effect was unique to the metha-
choline provocation assay and did not occur with another nonspe-
cific stimulus (i.e., exposure to serotonin). Moreover, this baseline
effect in response to methacholine was independent of the number
of eosinophils recruited to the lung and did not obviate the increase
in Ag-mediated AHR. Because baseline eosinophil numbers are
very low, and these cells are not activated, it is likely that only low
levels of MBP would be present in wild-type mice, and thus only
a fraction of the pulmonary M2 muscarinic receptors will be oc-
cupied (i.e., blocking the negative feedback loop regulating neu-
ronal acetylcholine release). In this paradigm, the baseline equi-
librium between MBP and pulmonary M2 receptors would shift
dramatically during allergic inflammatory responses because of the
increased availability of systemic sources of MBP and, more im-
portantly, the availability of localized pulmonary sources of MBP
(i.e., strategically located eosinophils within the lung). However,
the data presented here are in conflict with this model, as Ag-
induced increases in AHR occurred equally in the presence or the
absence of mMBP-1. These observations evoke two mutually ex-
clusive conclusions regarding ESGP effector function in this mu-
rine model: 1) functionally significant degranulation of eosinophils
(as assessed by the release of mMBP-1) is not occurring in this
OVA-mediated mouse model of asthma; or 2) degranulation by
eosinophils is occurring, but the temporal and/or spatial release of
ESGPs is functionally insignificant with respect to the develop-
ment of AHR. Although qualitative data exist suggesting that
mMBP is released as part of some OVA-mediated models (37),
FIGURE 6. The airway reactivity of naive mMBP-12/2 mice is attenuated relative to that in wild-type animals in response to methacholine, but not
serotonin, provocation. The airway reactivity (percentage of the baseline PENH (y-axis)) of naive wild-type and mMBP-12/2 mice (n5 8 mice/group) was
assessed by whole-body plethysmography as a function of increasing doses of nebulized methacholine/serotonin (x-axis). The airway reactivity in each
panel was plotted (6SEM (error bars)) as the percent increase from the response observed after exposure to a saline aerosol.A, Methacholine dose-response
assays show that the threshold dose for methacholine-induced airflow changes in wild-type mice was lower than the dose required to induce equivalent
changes in mMBP-12/2 mice. Moreover, the absolute magnitude of these methacholine-induced changes was significantly higher in wild-type animals than
in mMBP-12/2 littermates.B, Dose-dependent airflow changes were not observed between naive (i.e., baseline) wild-type and mMBP-12/2 mice in a
serotonin-mediated provocation assay.p, p , 0.05, naive wild-type vs mMBP-12/2 mice.
FIGURE 7. Murine MBP-1 does not mediate OVA-induced increases in airway hyper-responsiveness in response to nonspecific stimuli (i.e., AHR).
Shown are methacholine (A) and serotonin (B) dose-response curves resulting from group mean data derived from four cohorts of animals (n5 8–10
mice/group), including naive and OVA-treated wild-type and mMBP-12/2 mice. Airway reactivity (percentage of the baseline PENH (y-axis)) in response
to increasing doses of nebulized methacholine/serotonin (x-axis) was assessed by whole-body plethysmography. The ED200 is shown as an assessment of
the threshold dose of methacholine required to induce a 2-fold increase in PENH from the observed baseline value.p, p , 0.05, naive mMBP-12/2 vs
OVA-treated mMBP-12/2 mice.
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this study does not demonstrate the extent of this phenomenon, nor
does it causatively link the release of mMBP-1 with AHR. Thus,
a review of the existing literature regarding the mouse models of
inflammation would suggest that either there is OVA model vari-
ability associated with the relative contribution of eosinophil de-
granulation to the development of AHR or, unlike human eosino-
phils from asthma patients (38; see review in Ref. 39), functionally
significant eosinophil degranulation does not occur in murine
OVA models of respiratory inflammation (40, 41).
This apparent difference observed between MBP-1 effector
function in patients with asthma and the murine models may reflect
the chronic inflammatory character of this disease state in humans.
Human MBP-1 deposition probably occurs over long periods of
time (i.e., months/years) and cumulatively correlates with both
AHR and histopathologic airway epithelial changes, whereas ex-
tensive (and chronic) eosinophil degranulation does not occur in
the 96-h challenge interval of most OVA protocols. However, our
unpublished data assessing murine vs human eosinophil respira-
tory burst and release of EPO in vitro demonstrate that mouse
eosinophil degranulation is greater than an order of magnitude less
under conditions that elicit this response from human cells. These
data imply that the incongruities between human patients and
mouse models of asthma are probably not an issue of the OVA
model, but reflect species differences in eosinophil effector func-
tion. We would propose that degranulation occurs more readily in
human eosinophils and is required, because of unique effector
functions that were/are evolutionarily advantageous to primates
and not rodents. The resolution of this quandary will probably have
significant implications regarding other roles of eosinophils in
mouse models of human disease, as some, but not all, effector
functions will have been conserved during mammalian evolution.
The data presented here do not preclude the participation of
other ESGPs in the development of Ag-induced lung dysfunction.
However, the demonstration that OVA-induced AHR in the mouse
occurs independently of mMBP-1 suggests a parsimonious expla-
nation of previous studies that showed a disassociation of eosin-
ophil effector function and AHR; Ag-induced AHR in mouse mod-
els of asthma may not be causatively linked to the release of
ESGPs. Studies in which AHR occurred in the absence of a sig-
nificant airways eosinophilia (22–25) or that disassociated AHR
from eosinophil recruitment to the lung (27) were apparently as-
sessing an mMBP-1-independent phenomena. This lack of an ob-
served effect mediated by the release of the most abundant ESGP
suggests that AHR is either dependent on other less abundant
ESGPs, eosinophil effector functions other than degranulation, or
is a pathophysiologic response mediated by the activity of another
cell type(s). As noted in several studies, activated CD41 T cells
recruited to the lung in response to allergen challenge were likely
candidates to mediate eosinophil-independent effects (25, 30, 31).
Furthermore, genetic studies linking AHR and T cells (29, 32) or
studies linking AHR and T cell-derived cytokines that have little or
no direct effect on eosinophil proliferation and/or function (e.g.,
pulmonary expression of IL-13) (27, 28), further support a rela-
tionship between AHR and T cells. The implicit conclusion that
arises is that a direct causative link between eosinophil degranu-
lation (i.e., the release of ESGPs such as mMBP-1) and the de-
velopment of AHR remains an elusive, and potentially unattain-
able, goal in the mouse.
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